The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases. Forty-three neutropenic patients with infections (rhG-CSF group) were treated with AZT (2 g) and CLDM (600 mg) 2-3 times daily as well as rhG-CSF (Lenograstim or Filgrastim: 2-5 id/kg/day). The clinical efficacy of this regimen was compared to that obtained in 44 febrile neutropenic patients, with hematologic diseases, who received only AZT and CLDM in a previous study (historical control group).
In patients with hematologic malignancies, as exemplified by lymphoma and acute leukemia, life-threatening infections such as septicemia and pneumonia are not uncommon when severe neutropenia develops due to the underlying diseases or myelosuppression after chemotherapy or radiotherapy1).
Identification of the causative pathogens is often difficult in patients who have infections associated with neutropenia2'3), and it is necessary for such infections to be treated empirically with broad-spectrum antimicrobial agents before identification of the causative organisms2'4'5). Aztreonam (AZT) is active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa, while clindamycin (CLDM) is effective against aerobic gram-positive bacteria and anaerobic bacteria6'7'8'). Therefore, a broad spectrum of antibacterial activity can be provided by using these two drugs in combination, and excellent results have been obtained in patients with various infections9).
The combination of AZT and CLDM has also been used to treat infections in patients with neutropenia due to hematologic malignancy. In 1990, we reported on the excellent efficacy of combination therapy with AZT and CLDM for severe infections in patients with hematologic diseases10).
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) not only increases the neutrophil count but also enhances leukocyte function11). Accordingly, combination therapy with rhG-CSF and antimicrobial agents has been studied in neutropenic animal models12,13) and in patients14) with infections. However, the efficacy of rhG-CSF for treating infections in neutropenic patients has not yet been confirmed. 
Results

Handing of the subjects
Combination therapy with AZT and CLDM plus rhG-CSF was performed in a total of 91 patients (rhG-CSF group).
However, 48 patients were excluded from this group because of protocol violations (e.g. prior administration of rhG-CSF or concomitant use of antifungal or anticancer agents), leaving 43 patients. Of the 250 patients in our previous study of AZT and CLDM therapy"), 206 were excluded based on the same inclusion or exclusion criteria as applied to the rhG-CSF group, and the remaining 44 served as historical controls. 2. Clinical characteristics (Table 1 ) The mean ages of the rhG-CSF and historical control groups were 45.1 years and 52.6 years respectively. The mean durations of AZT administration were 8.5 and 8.8 days for the respective groups, and the daily doses were 3.9 and 4.9 g. There was a significant difference in daily dose between the rhG-CSF group and the historical control group (p <0.01). The corresponding values for CLDM were 8.5 and 9.0 days, 1,861 and 2,009 mg. Concerning the underlying diseases, lymphoma predominated in the rhG-CSF gruop while acute leukemia was more common in the historical control group (Table 1) .
Clinical efficacy
Clinical efficacy was determined on the basis of the efficacy rate (the percentage of good or excellent responses).
The efficacy rates determined by the Evaluation Committee were 69.8% and 65.9% for the rhG-CSF and historical control groups, respectively. There was no significant difference between the two groups ( Table 2) .
Clinical efficacy in relation to the type of infection is presented in Table 3 . Efficacy varied 
